Viking Therapeutics, Inc. (VKTX)

NASDAQ

$36.18

-$0.90 (2.43%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$35.95$37.24

Open $36.77

52 Week Range

$18.92$48.55

Previous Close $37.08

Market Cap4.09B

Volume1.72M

Avg Volume4.41M

P/E (TTM)-17.12

EPS (TTM)$-2.11

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Viking Therapeutics, Inc.

NOV252025

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Source: PRNewsWire•20 days ago

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it wil...

NOV192025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Source: PRNewsWire•27 days ago

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735 SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDA...

NOV62025

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Source: PRNewsWire•39 days ago

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-s...

NOV42025

Viking Therapeutics to Participate at Upcoming Investor Conferences

Source: PRNewsWire•41 days ago

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the com...

OCT292025

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Source: PRNewsWire•47 days ago

Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025 SAN DIEGO , Oct. 29, 2025 /PRNewswire...

OCT222025

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Source: PRNewsWire•54 days ago

Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule VK2735 Phase 1 Maintenance Dosing Study Underway Additional Phase 2a VENTURE Study Data to be Presented at ObesityWeek ...

OCT212025

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Source: PRNewsWire•55 days ago

Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VK...

OCT152025

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Source: PRNewsWire•61 days ago

Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of nov...